Cyclerion Accounts Payable vs Total Liab Analysis
| CYCN Stock | USD 2.75 0.18 6.14% |
Cyclerion Therapeutics financial indicator trend analysis is way more than just evaluating Cyclerion Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclerion Therapeutics is a good investment. Please check the relationship between Cyclerion Therapeutics Accounts Payable and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.
Accounts Payable vs Total Liab
Accounts Payable vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclerion Therapeutics Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Cyclerion Therapeutics' Accounts Payable and Total Liab is 0.52. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of Cyclerion Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclerion Therapeutics' Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Cyclerion Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., Cyclerion Therapeutics' Accounts Payable and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.52 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Accounts Payable
An accounting item on the balance sheet that represents Cyclerion Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cyclerion Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Cyclerion Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclerion Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.At this time, Cyclerion Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 23rd of September 2024, Sales General And Administrative To Revenue is likely to grow to 46.15, while Issuance Of Capital Stock is likely to drop about 4.3 M.
Cyclerion Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Cyclerion Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclerion Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 186.5M | 115.4M | 59.3M | 18.1M | 13.4M | 12.7M | |
| Other Current Liab | 404K | 176K | 9.3M | 4.7M | 888K | 843.6K | |
| Total Current Liabilities | 18.2M | 17.0M | 11.1M | 7.6M | 2.1M | 2.0M | |
| Total Stockholder Equity | 97.7M | 59.5M | 48.2M | 10.5M | 11.3M | 10.7M | |
| Net Tangible Assets | 97.7M | 98.4M | 48.2M | 10.5M | 12.0M | 11.4M | |
| Retained Earnings | (85.6M) | (163.4M) | (215.1M) | (259.2M) | (264.4M) | (251.2M) | |
| Accounts Payable | 3.3M | 1.4M | 1.8M | 3.0M | 1.2M | 1.7M | |
| Cash | 94.9M | 54.4M | 54.0M | 13.4M | 7.6M | 7.2M | |
| Other Assets | 5.5M | 50.0M | 2.4M | 2.0M | 2.3M | 2.2M | |
| Inventory | 2.0M | 816K | 928K | 805K | 925.8K | 709.5K | |
| Other Current Assets | 2.9M | 3.2M | 468K | 537K | 11K | 10.5K | |
| Other Stockholder Equity | 183.4M | 222.9M | 263.3M | 269.6M | 275.7M | 168.8M | |
| Total Liab | 88.7M | 55.9M | 11.1M | 7.6M | 2.1M | 2.0M | |
| Total Current Assets | 101.2M | 58.5M | 55.5M | 14.8M | 8.0M | 7.6M | |
| Accumulated Other Comprehensive Income | (15.5M) | (20K) | (27K) | (23K) | (12K) | (12.6K) | |
| Property Plant Equipment | 79.8M | 6.9M | 1.5M | 1.2M | 1.1M | 1.0M | |
| Property Plant And Equipment Net | 6.5M | 79.8M | 50.3M | 1.5M | 1.2M | 0.0 | |
| Non Current Assets Total | 85.3M | 56.9M | 3.9M | 3.3M | 5.4M | 5.1M | |
| Non Currrent Assets Other | 540K | 2.8M | 2.4M | 2.0M | 5.4M | 5.6M | |
| Common Stock Shares Outstanding | 1.4M | 1.5M | 2.0M | 2.2M | 2.3M | 1.9M | |
| Liabilities And Stockholders Equity | 186.5M | 115.4M | 59.3M | 18.1M | 13.4M | 12.7M | |
| Net Invested Capital | 97.7M | 63.0M | 48.2M | 10.5M | 11.3M | 10.7M | |
| Property Plant And Equipment Gross | 79.8M | 6.9M | 3.7M | 3.4M | 126K | 119.7K | |
| Net Working Capital | 82.9M | 41.5M | 44.4M | 7.2M | 5.9M | 5.6M |
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
| 0.52 | MBIO | Mustang Bio | PairCorr |
| 0.45 | RANI | Rani Therapeutics | PairCorr |
| 0.41 | REVBW | Revelation Biosciences | PairCorr |
| 0.36 | DYAI | Dyadic International | PairCorr |
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Cyclerion Stock
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.